Towards a molecular classification of colorectal cancer.

Int J Colorectal Dis

Department of Pathology, University of Queensland, Australia.

Published: November 1999

The basic mechanisms driving genetic instability underlie a new molecular classification of colorectal cancer that is assuming diagnostic and prognostic importance. These mechanisms and the criteria for stratifying colorectal cancer as microsatellite stable (MSS), microsatellite instability-low (MSI-L) and microsatellite instability-high (MSI-H) are presented. This molecular classification is discussed in relation to morphogenesis, histopathology, behaviour and investigation of prognostic biomarkers in colorectal cancer. Clinical applications are considered, emphasising the role of the pathologist in identifying and working up cases of suspected hereditary non-polyposis colorectal cancer. The principal value of microsatellite instability testing is in relation to the diagnosis of hereditary non-polyposis colorectal cancer. Demonstration of loss of DNA mismatch repair genes, notably hMLH1 and hMSH2, by immunohistochemistry provides additional diagnostic information and may reduce the requirement for microsatellite instability testing. It is likely that testing for DNA mismatch repair will be adopted as a routine for colorectal cancer as more is learned of the distinctive pathobiology and behaviour of MSS, MSI-L and MSI-H cancers.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s003840050211DOI Listing

Publication Analysis

Top Keywords

colorectal cancer
28
molecular classification
12
classification colorectal
8
hereditary non-polyposis
8
non-polyposis colorectal
8
microsatellite instability
8
instability testing
8
dna mismatch
8
mismatch repair
8
colorectal
7

Similar Publications

Development and pilot testing of INTERVENER, a web-based tool to match barriers to the cancer continuum organization to evidence-based interventions.

BMC Health Serv Res

January 2025

Early Detection, Prevention & Infections Branch, International Agency for Research on Cancer, 25 Avenue Tony Garnier, Lyon, 69366 Cedex 07, France.

Background: Barriers to the cancer continuum organization and interventions to approach them have been identified; however, there is a lack of a tool matching them. Our aim was to develop a web-based tool to identify the main barriers to the process of the cancer continuum organization, and propose matched evidence-based interventions (EBI) to overcome them.

Methods: A questionnaire on barriers at six steps of the process of the cancer continuum organization was answered by collaborators.

View Article and Find Full Text PDF

Background: Colorectal cancer (CRC) is a common gastrointestinal cancer, and even though oxaliplatin chemotherapy is effective, there is a high likelihood of relapse, indicating the presence of oxaliplatin-resistant CRC. Therefore, it is crucial to comprehend the molecular mechanisms of oxaliplatin resistance and develop effective strategies to counter drug resistance. Numerous studies have demonstrated the close association between microRNAs (miRNAs) and drug resistance in CRC.

View Article and Find Full Text PDF

Impact of pathological complete response on survival in gastric cancer after neoadjuvant chemotherapy: a propensity score matching analysis.

BMC Gastroenterol

January 2025

Department of General Surgery (Gastrointestinal Surgery, Unit 1), The Sixth Affiliated Hospital, Sun Yat-sen University, 26 Yuancun Erheng Road, Guangzhou, 510655, China.

Purpose: The survival benefits of neoadjuvant chemotherapy (NAC) for locally advanced gastric cancer (LAGC) patients are inconsistent. This study aims to investigate how different tumor regression grades (TRG) influence the survival gains associated with NAC treatment.

Methods: This study compared the treatment outcomes of patients who underwent CSC (neoadjuvant chemotherapy - surgery - adjuvant chemotherapy) with those receiving traditional SC (surgery - adjuvant chemotherapy) treatment.

View Article and Find Full Text PDF

Background: Microsatellite instability-high (MSI-H) metastatic colorectal cancer (CRC) patients are the dominant population in immune checkpoint blockade treatments, while more than half of them could not benefit from single-agent immunotherapy. We tried to identify the biomarker of MSI-H CRC and explore its role and mechanism in anti-PD-1 treatments. Tumor-specific MHC-II was linked to a better response to anti-PD-1 in MSI-H CRC and CD74 promoted assembly and transport of HLA-DR dimers.

View Article and Find Full Text PDF

Anamorelin, a highly selective ghrelin receptor agonist, enhances appetite and increases lean body mass in patients with cancer cachexia. However, the predictors of its therapeutic effectiveness are uncertain. This study aimed to investigate the association between the Glasgow prognostic score (GPS), used for classifying the severity of cancer cachexia, the therapeutic effectiveness of anamorelin, and the feasibility of early treatment based on cancer types.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!